Q-omics provides the consensus-scored RPL7L1P2 profile across patient tissues and cancer cell-line models. RPL7L1P2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, RPL7L1P2 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, RPL7L1P2 RNA expression shows 7,604 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight DLBC, STAD, and CCRCC as cancer lineages where RPL7L1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7L1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7L1P2 survival associations across molecular data types. RPL7L1P2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7L1P2 RNA expression–survival associations across cancer types. High RPL7L1P2 expression shows unfavorable associations in DLBC, LUSC, ESCA, PCPG and SKCM, but favorable associations in COAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for RPL7L1P2 RNA expression.
This table summarizes RPL7L1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7L1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7L1P2 shows higher tumor expression in STAD and LIHC. The STAD box plot shows higher RPL7L1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.114, t-test p = .001).
This table shows molecular features associated with RPL7L1P2 in patient tissues and cancer cell lines. In patient samples, RPL7L1P2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
